BALAXI PHARMACEUTICALS LIMITED

rs,

etary & Compliance Officer Encl: A/a Registered Office: Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase lIl, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096 CIN: L25191TG1942PLC12

400 billion

on @ rroduct Sourcing Regions Balaxi aiaxi Existing/targeted markets have aggregate GDP of S 400 billion and pharma imports of S 6 billion Tfi 9 Key Milestones Started business supplying white label

6 billion

laxi aiaxi Existing/targeted markets have aggregate GDP of S 400 billion and pharma imports of S 6 billion Tfi 9 Key Milestones Started business supplying white labelled products to customers in Afri

INR 47.57 crore

nduras and El Salvador Successfully completed fund raising exercise through Preferential issue — INR 47.57 crore Capex plans — Establishing Company’s first Pharma Formulation manufacturing facility in Hyderaba

21%

aphies, we successfully unlocked new growth levers. Our consolidated revenue registered a healthy 21% growth, underpinned by satisfactory performance in both Africa and Latin America. In Africa, we su

INR 38.29

racted in and due for settlement in USD, this has resulted in a loss on revaluation of 3.65bn AOA (INR 38.29 cr.) The corresponding INR amount has been shown as an exceptional item in the profit and loss state

INR 2.39

wn as an exceptional item in the profit and loss statement of FY24 — resulted in negative profit of INR 2.39 - Balaxi cr inthe previous financial year (FY24) Pharma Product Mix — FY25 Geographies Produc

51.7%

Share (INR) *Exceptional Item pertaining to Q4 FY24 : 1.08 cr. Balaxi Q4 FY24 59.83 30.95 51.7% 11.68 19.5% 10.93 18.3% 2.08 Pharma Product Mix — Q4 FY25 Geographies Products m Afric

19.5%

*Exceptional Item pertaining to Q4 FY24 : 1.08 cr. Balaxi Q4 FY24 59.83 30.95 51.7% 11.68 19.5% 10.93 18.3% 2.08 Pharma Product Mix — Q4 FY25 Geographies Products m Africa* u LATM**

18.3%

Item pertaining to Q4 FY24 : 1.08 cr. Balaxi Q4 FY24 59.83 30.95 51.7% 11.68 19.5% 10.93 18.3% 2.08 Pharma Product Mix — Q4 FY25 Geographies Products m Africa* u LATM** LU u Branded

“L] ° General Oral Solid Dosage (OSD) formulations Targeting demand for high quality products in Latin American markets Allows full backward integration of supply chain Plant Commissioning and Validation by the Q1 of FY26 Historically, Balaxi has successfully executed on its “produce, stock and sell” model.”

“Over the medium term, Balaxi sees several new market opportunities opening up for its product lines.”

“Stickler for well-defined systems and processes Initiated and leads the consumer products business FINANCIAL HIGHLIGHTS Balaxi “FY25 has been a pivotal year in Balaxi Pharmaceutical’s growth journey.”

“Looking ahead, we remain focused on - Operationalising our first formulation facility in FY26; Expanding our branded formulations in existing and new markets; Investing in regulatory filings and pipeline development to enter higher-value markets; Continue to strengthen internal systems and supply chain resilience.”

“Balaxi Q4 FY24 59.83 30.95 51.7% 11.68 19.5% 10.93 18.3% 2.08 Pharma Product Mix — Q4 FY25 Geographies Products m Africa* u LATM** LU u Branded = Generics Dosage Forms Therapeutic Areas o AREE m Tablets = Injectables = Liquids = Capsules m Others m Antibiotics = Analgesic = Anti-malaria A = Others Balax’ *Africa: Angola and Central African Republic *LATM - Guatemala, Dominican Republic, Hondurus and El Salvador ' Core Strategy: Enter, Expand & Excel Balaxi in 2020: Business Consolidation s ..”

Registered Office

1

Expansion initiated

1

Registered Office

Plot No. 409, H. No. 8-2-293, Maps Towers, 3rd Floor, Phase lIl, Road No. 81, Jubilee Hills, Hyderabad (T.G.) - 500 096 CIN: L25191TG1942PLC121598 Phone: +91 40 23555300 | Email: info@balaxi.in | Website: www.balaxipharma.in Balaxi Pharmaceuticals Limited Branded IPR-driven Pharma Player in Frontier Markets Investor Presentation ' Disclaimer Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Balaxi Pharmaceuticals Limited will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances. Balaxi 04 Corporate Snapshot 1

Expansion initiated

Ecuador, Chile (Latin America) 915 product registrations in Seven countries 300+ registrations submitted or in the pipeline Establishing the Company’s first pharmaceutical formulation facility in Hyderabad Successful process being replicated in other frontier markets; expansion plans in other global markets over near to medium term Centralized digital procurement, regulatory management and customized CRM tools Key Success Factors Market Selection Methodology = Focus on countries with high-potential economic growth framework = |dentify non-English speaking countries with similar characteristics = Low competitive intensity and potential to establish top-2 position = On-ground feedback mechanism allows deep understanding of demand dynamics = As population crosses prosperity thresholds, healthcare spends expand exponentially Human Capital Management = Established unique ecosystem of 100+ Indian expatriates in operating geographies = Financial security ecosystem for key personnel, creating